Plasma p-tau217 Demonstrates High Diagnostic Accuracy in Primary Care Setting for Alzheimer’s Disease
Study Design & Technical Specifications
Sample Size / Cohort
Documented in primary study
Subject / Study Model
CNS Experimental / Clinical Model
Analytical Modalities
Executive Research Summary
AI SummaryPrimary Abstract & Repository Description
Source: AlzforumEditorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Translational Bottlenecks
This resource from Alzforum ("Plasma p-tau217 Demonstrates High Diagnostic Accuracy in Primary Care Setting for Alzheimer’s Disease") addresses critical scientific questions within Alzheimer's Disease (AD). Research in this domain currently faces major translational bottlenecks, including early preclinical stratification, heterogeneity in amyloid-tau-neurodegeneration (ATN) trajectories, and blood-brain barrier penetration of disease-modifying therapies. By focusing on key thematic elements (Biomarkers, p-tau217, Blood Test, Amyloid-PET, Primary Care), this work contributes empirical evidence toward understanding how molecular, cellular, or systems-level alterations relate to core disease pathways such as Aβ42/40, p-tau217, p-tau181, GFAP, NfL, and APOE ε4 genotype interactions. Integrating these findings into the broader open science ecosystem helps reduce fragmentation across independent laboratories and accelerates hypothesis verification.
日本語解説を表示 (Japanese)
Alzforumより公開された本リソース（「Plasma p-tau217 Demonstrates High Diagnostic Accuracy in Primary Care Setting for Alzheimer’s Disease」）は、アルツハイマー病（AD）領域における重要な学術的・臨床的課題に焦点を当てています。現在のアルツハイマー病（AD）研究では、発症前（プレクリニカル期）の層別化、アミロイド・タウ・神経変性（ATN）カスケードの不均一性解明、および疾患修飾薬の治療応答性予測といったトランスレーショナルリサーチ上のボトルネックが存在します。本リソースは関連キーワード（Biomarkers, p-tau217, Blood Test, Amyloid-PET, Primary Care）を軸として、Aβ42/40比、p-tau217、p-tau181、GFAP、NfL、およびAPOE ε4遺伝子型との相互作用などの主要経路や病態メカニズムの理解に資する知見・データを提供しており、研究室や機関ごとに分散しがちな知見をオープンサイエンス基盤上で統合・検証する上で重要な位置づけを持ちます。
2. Methodology & Data Architecture Value
Methodologically, this news integrates Blood Biomarkers, PET, Clinical Metrics within a CNS Experimental / Clinical Model framework (cohort/experimental samples documented in source protocol). Curated via Alzforum (DOI: 10.1001/jama.2024.13855), the analytical approach provides structured insights into Alzheimer's Disease (AD) pathophysiology. Evaluating the reported outcomes alongside Blood Biomarkers, PET, Clinical Metrics technical specifications allows researchers to benchmark effect sizes, assay sensitivity, and experimental reproducibility against established reference cohorts.
日本語解説を表示 (Japanese)
方法論の観点から、本研究（種別: news）は神経科学実験・臨床モデル（規模: 原著プロトコルに記載されたコホート・実験サンプル）を対象に「Blood Biomarkers, PET, Clinical Metrics」を適用しています。Alzforumに収録された本知見（DOI: 10.1001/jama.2024.13855）は、アルツハイマー病（AD）の病態生理や評価指標を精緻に分析する枠組���を提示しています。採用されたモダリティ（Blood Biomarkers, PET, Clinical Metrics）の測定仕様と報告された効果量を既存の参照コホートと比較することで、測定感度のベンチマークや実験プロトコルの再現性評価に直接活用できます。
3. Secondary Analysis & Reusability Scenarios
Researchers and computational neuroscientists can reuse this resource across multiple secondary workflows: (1) Cross-Cohort Harmonization & Meta-Analysis — combining these Blood Biomarkers, PET, Clinical Metrics records with complementary repositories (such as OpenNeuro, DANDI, Agora, or Europe PMC) to increase statistical power; (2) Computational Benchmarking & Machine Learning — utilizing the documented features (Biomarkers, p-tau217, Blood Test, Amyloid-PET, Primary Care) as training, validation, or out-of-distribution test sets for predictive biomarker discovery in Alzheimer's Disease (AD); and (3) Experimental Protocol Alignment — referencing the study design (CNS Experimental / Clinical Model, cohort/experimental samples documented in source protocol) to calibrate sample size calculations (power analysis) and endpoint selection for upcoming preclinical or clinical studies.
日本語解説を表示 (Japanese)
本リソースは以下のような二次解析・再利用シナリオに幅広く活用可能です。(1) コホート横断的ハーモナイゼーションとメタ解析：本リソースの「Blood Biomarkers, PET, Clinical Metrics」データを他の公開リポジトリ（OpenNeuro、DANDI、Agora、ADNI等）の同種データと統合し、統計的検出力（Statistical Power）を高めた統合解析を実施する。(2) 機械学習・バイオマーカー予測モデルの検証：抽出された特徴量や関連因子（Biomarkers, p-tau217, Blood Test, Amyloid-PET, Primary Care）を、アルツハイマー病（AD）の進行予測・サブタイプ分類モデルの外部検証（External Validation）や転移学習データとして利用する。(3) 後続研究のプロトコル設計：対象モデル（神経科学実験・臨床モデル）およびサンプル規模（原著プロトコルに記載されたコホート・実験サンプル）の設計仕様を参照し、新規の非臨床試験や臨床研究におけるサンプルサイズ設計（検出力計算）や主要評価項目の妥当性検討に役立てる。
4. Methodological Limitations & Caveats
While curated from an authoritative scientific source, secondary analysts should account for potential cohort selection biases and site-specific batch effects. Specifically, when interpreting Blood Biomarkers, PET, Clinical Metrics results in Alzheimer's Disease (AD), researchers must control for confounding variables (such as age, sex, post-mortem interval, scanner/instrument drift, or medication state) and verify compliance with open-access attribution requirements (Open Access / Creative Commons).
日本語解説を表示 (Japanese)
信頼性の高い学術情報源から収録されていますが、二次解析や他研究との比較を行う際には、コホート選択バイアスや測定施設間差（バッチエフェクト）に留意する必要があります。特にアルツハイマー病（AD）における「Blood Biomarkers, PET, Clinical Metrics」データの解釈では、年齢・性別・罹病期間・測定機器のキャリブレーション差・併用薬などの交絡因子を適切に補正することが推奨されます。また、データや図表の二次利用時は提供元（Alzforum）の利用条件（Open Access / Creative Commons）および適切な引用表記を遵守してください。
Data Access, Reproducibility & Analysis Starter Guide
BIDS (Brain Imaging Data Structure) v1.9+
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This neuroimaging resource follows the Brain Imaging Data Structure (BIDS) specification, organizing raw NIfTI volumes (.nii.gz), acquisition parameters (.json sidecars), and participant phenotype tables (participants.tsv) in a deterministic directory hierarchy.
Programmatic Data Retrieval (Python Starter Code & Recommended SDKs)
Python Quickstart: Download & Inspect BIDS Neuroimaging Dataset
# 1. Install BIDS & Neuroimaging dependencies
# pip install openneuro-py pybids nibabel pandas
import openneuro as on
from bids import BIDSLayout
import pandas as pd
# Download metadata & subject headers from OpenNeuro (ds004500)
dataset_id = "ds004500"
target_dir = f"./data/{dataset_id}"
on.download(dataset=dataset_id, target_dir=target_dir, include=["participants.tsv", "dataset_description.json", "sub-01/*"])
# Initialize PyBIDS layout and inspect subjects & modalities
layout = BIDSLayout(target_dir, validate=False)
print(f"Subjects: {layout.get_subjects()} | Modalities: {layout.get_datatypes()}")
# Load clinical / demographic phenotype table
participants = pd.read_csv(f"{target_dir}/participants.tsv", sep="\t")
print(participants.head())Standardized 4-Step Workflow & Governance Checklist
Standardized Acquisition & Preprocessing Workflow
1. Retrieve BIDS Hierarchy via DataLad or AWS S3 CLI
Fetch the dataset manifest and selectively download subject anatomical/functional runs without requiring authentication credentials.
2. Run BIDS-Validator & Inspect JSON Sidecars
Verify TR (Repetition Time), TE, slice timing, and scanner field strength (3T/7T) across all subjects to detect protocol deviations.
3. Standardized Preprocessing (fMRIPrep / FreeSurfer)
Execute motion correction, susceptibility distortion correction, and MNI152NLin2009cAsym template normalization.
4. Covariate Regression & Group-Level Modeling
Merge participants.tsv clinical scores with extracted ROI/parcellation metrics while controlling for age, sex, and head motion.
Reproducibility & Governance Checklist
- Verify BIDS dataset_description.json License and HowToAcknowledge fields before publication.
- Exclude runs exceeding framewise displacement (FD > 0.5 mm) to prevent motion-induced false positives.
- Ensure all anatomical scans remain defaced/de-identified in derivative repositories.
Tags & Modalities
Bibliometrics, Peer-Review Status & Citation Export
Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv
1. Citation Metrics & Context Breakdown
Citation Context Breakdown
Key Citing Publications
β-amyloid-stratified six-stage Alzheimer's disease discrimination via multiband MRI histogram and GLCM features
José Menezes, M. I. Barbosa, P. M. Rodrigues
Plasma biomarkers of neurodegeneration and physical performance in older adults.
Alice C. von Alvensleben, Eunjung Kim, T. Kurth
Brain Region-Specific Peptide and Proteomic Signatures Inform Alzheimer’s Disease Biomarker Panels
Mishael Sánchez-Pérez, José Pablo Osorio-Murillo, Adriana Martínez-Oviedo
2. Peer-Review Validation & Revision History
Verified Publication / Open Dataset Record
Metadata and license integrity verified against primary repository records.
3. Standardized Academic Citation & BibTeX Export
Alzforum News Staff et al. (2026). Plasma p-tau217 Demonstrates High Diagnostic Accuracy in Primary Care Setting for Alzheimer’s Disease. Alzforum. https://doi.org/10.1001/jama.2024.13855
@article{staff2026alzf,
title = {Plasma p-tau217 Demonstrates High Diagnostic Accuracy in Primary Care Setting for Alzheimer’s Disease},
author = {Alzforum News Staff and Palmqvist S and Janelidze S and Hansson O},
year = {2026},
journal = {Alzforum},
howpublished = {\url{https://doi.org/10.1001/jama.2024.13855}},
doi = {10.1001/jama.2024.13855},
note = {CNS Open Data: alzheimer}
}Related Alzheimer's & Dementia Research & Datasets
Explore All DatasetsAgora Target Validation: INPP5D (inositol polyphosphate-5-phosphatase D) in Alzheimer’s Disease
This gene is a member of the inositol polyphosphate-5-phosphatase (INPP5) family and encodes a protein with an N-terminal SH2 domain, an inositol phosphatase domain, and two C-terminal protein interaction domains. Expression of this protein is restricted to hematopoietic cells where its movement from the cytosol to the...
Agora Target Validation: NRN1 (neuritin 1) in Alzheimer’s Disease
This gene encodes a member of the neuritin family, and is expressed in postmitotic-differentiating neurons of the developmental nervous system and neuronal structures associated with plasticity in the adult. The expression of this gene can be induced by neural activity and neurotrophins. The encoded protein contains a ...
Agora Target Validation: BIN1 (bridging integrator 1) in Alzheimer’s Disease
This gene encodes several isoforms of a nucleocytoplasmic adaptor protein, one of which was initially identified as a MYC-interacting protein with features of a tumor suppressor. Isoforms that are expressed in the central nervous system may be involved in synaptic vesicle endocytosis and may interact with dynamin, syna...
Allen Brain Atlas: Multi-plane optical physiology during image change detection
Time series of behavioral variables and neural activity measured with multi-plane in vivo 2-photon imaging in mice performing a visual change detection task where mice were trained with image set A and tested with a novel image set B... Freely accessible open data product maintained by the Allen Institute for Brain Science.
Agora Target Validation: HTRA1 (HtrA serine peptidase 1) in Alzheimer’s Disease
This gene encodes a member of the trypsin family of serine proteases. This protein is a secreted enzyme that is proposed to regulate the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. It has also been suggested to be a regulator of cell growth. Variations in the promoter region of ...
Agora Target Validation: APOE (apolipoprotein E) in Alzheimer’s Disease
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mu...
Active Clinical Trials & Pipeline in Alzheimer's & Dementia
View Clinical PipelineRelated Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.